MDAM is a non-polyglutamylatable antifolate for the treatment of solid tumors, rheumatoid arthritis and psoriasis. MDAM is chemically related in its structure to methotrexate (MTX), which is widely used for cancer, rheumatoid arthritis and immunosuppression. Unlike MTX, MDAM does not undergo the same intracellular metabolism as MTX and it also appears to bypass the common forms of antifolate-type drug resistance and in preclinical studies has demonstrated selective cancer cell uptake and superior dose intensity, safety and antitumor activity relative to MTX. Phase 1 oncology clinical trials for racemic MDAM have been completed at The Johns Hopkins Oncology Center and M.D. Anderson Cancer Center.
Preclinical and Clinical Summary